Products

Savoy's patented discovery is a unique and remarkable new monoclonal antibody treatment targeted at a protein found on the surface of cancer cells and virally infected cells. It binds specifically to the targeted infected cell and destroys it while maintaining the integrity of non-infected cells. Savoy has conducted extensive pre-clinical testing and proven its technology across a variety of viruses and cancers.
The result of this has lead to the patents and further development of: Oncoprev™ for the treatment of liver cancer and Viroprev™ for the treatment of Hepatitis C and HIV.

Product Development Strategy

Savoy has conducted extensive pre-clinical testing and proven its technology across a variety of cancers and viruses. The result of this has led to the patents and further development of 2 products, Oncoprev™ to treat cancers and Viroprev™, for the treatment of viral diseases.
Savoy Pharmaceuticals, Inc.'s strategy is to further develop Oncoprev™ and Viroprev™ to the stage where we can demonstrate their potential for clinical viability, and then to license the products to an established pharmaceutical company with the resources necessary to complete clinical trials and bring the product to market. The company outsources the research and development of Oncoprev™ and Viroprev™.